ABSTRACT: Pancreatic-type ribonucleases are secretory enzymes that catalyze the cleavage of RNA. Recent efforts have endowed the homologues from cow (RNase A) and human (RNase 1) with toxicity for cancer cells, leading to a clinical trial. The basis for the selective toxicity of ribonuclease variants for cancerous versus noncancerous cells has, however, been unclear. A screen for RNase A ligands in an array of mammalian cell-surface glycans revealed strong affinity for a hexasaccharide, Globo H, that is a tumor-associated antigen and the basis for a vaccine in clinical trials. The affinity of RNase A and RNase 1 for immobilized Globo H is in the low micromolar−high nanomolar range. Moreover, reducing the display of Globo H on the surface of human breast adenocarcinoma cells with a small-molecule inhibitor of biosynthesis or a monoclonal antibody antagonist decreases the toxicity of an RNase 1 variant. Finally, heteronuclear single quantum coherence (HSQC) NMR spectroscopy showed that RNase 1 interacts with Globo H by using residues that are distal from the enzymic active site. The discovery that a systemic human ribonuclease binds to a moiety displayed on human cancer cells links two clinical paradigms and suggests a mechanism for innate resistance to cancer.
■ INTRODUCTION
Pancreatic-type ribonucleases (RNases) are small cationic proteins that are secreted by vertebrate cells. 1 RNase A, a renowned enzyme from cows, and RNase 1, its most prevalent human homologue, are highly efficient catalysts of RNA cleavage. 2 Moreover, when engineered to evade the cytosolic ribonuclease inhibitor protein (RI 3 ), both RNase A and RNase 1 are endowed with cytotoxicity. 4−8 The putative mechanism for this cytotoxicity involves internalization of an RNase via endosomes, translocation into the cytosol, and cleavage of cellular RNA, which leads to apoptosis. 9 Surprisingly, the cytotoxic activity of RI-evasive RNases is specific for cancer cells, and a variant of RNase 1 is undergoing clinical trials as a cancer chemotherapeutic agent. 10 The basis for the specificity of RI-evasive variants for cancerous versus noncancerous cells has been unclear. Both normal and cancerous cells contain RI at similar levels. 11 Thus, RI evasion is unlikely to play a major role in specific toxicity for cancer cells.
The surface of cancer cells is more anionic than that of noncancerous cells due to increases in glycosaminoglycan profile, phospholipid composition, and glycosphingolipid exposure. 12 In addition, cancer cells undergo constitutive endocytosis more rapidly than do matched noncancerous cells. 13 These two factors could enhance the cellular uptake of RNases. 13, 14 Indeed, reducing the negative charge on a cell surface by diminishing the biosynthesis of heparan sulfate and chondroitin sulfate decreases net internalization, as does decreasing the positive charge of an RNase. 15, 16 These data provide some basis for the preferential susceptibility of cancer cells to RNase-mediated cytotoxicity. Still, we suspected that other factors were likely to contribute.
Eukaryotic cells are covered by a glycocalyx: an extensive network of polysaccharides. 17 The glycocalyx serves as a rich source of binding sites for receptors and ligands, as well as pathogens and toxins. The mammalian glycome is estimated to consist of a few hundred unique glycan structures on glycoproteins and glycolipids. 18 One such glycan is Globo H. Globo H is a neutral hexasaccharide glycosphingolipid. As a component of a glycolipid or glycoprotein, Globo H is located endogenously on the outer membrane of epithelial cells from mammary, uterine, pancreas, and kidney tissues. 19, 20 Importantly, immunohistological analyses have detected high levels of Globo H on the outer membrane of tumor specimens from small-cell lung, breast, prostate, lung, pancreas, gastric, ovarian, and endometrial tissues. 21 Moreover, high levels of this tumorassociated antigen correlate to a poor prognosis. 22, 23 Globo H could enable cancer cells to escape from immune surveillance, 24 and its intracellular binding to translin-associated factor X (TRAX) promotes angiogenesis, 25 which plays a critical role in the growth and spread of cancer. For these reasons and because its endogenous expression resides in tissues that are relatively inaccessible to the immune system, Globo H has become an attractive vaccine target for epithelial tumors. 26 This approach has been validated by the results of clinical trials in which treatment of cancer patients with up to 16 mg of a high-affinity, high-specificity 27 monoclonal antibody against Globo H (MBr1) resulted in no organ toxicity. 28 Accordingly, vaccines based on synthetic Globo H are advancing in clinical trials worldwide. 26,29−33 Despite the current therapeutic interest in Globo H, little is known about its functional role.
Here we screen a printed array of mammalian cell-surface glycans and discover that RNase A binds to Globo H. We measure the affinity of bovine RNase A and its human homologue, RNase 1, for Globo H in vitro using surfacebinding assays. Then, using two distinct types of antagonists, we show that breast adenocarcinoma cells that display less Globo H are less vulnerable to cytotoxic RNases. Finally, we use heteronuclear single quantum coherence (HSQC) NMR spectroscopy to identify those residues in RNase 1 that interact with Globo H. Together, these data suggest that the interaction of RNase 1 and Globo H could underlie a previously unknown endogenous anticancer activity in humans and provide a molecular basis for the efficacy of RNase 1 variants as cancer chemotherapeutic agents.
■ RESULTS
Glycan Array Screening. A printed array of 264 mammalian cell-surface glycans (Table S1 ) was screened for ligands for RNase A. Several glycan ligands were discovered by this screen (Figure 1) , and those fall into two categories: glycoproteins and unbranched glycans ( Table 1 ). The glycoproteins bound by RNase A are serum proteins with complex glycan modifications. Human α 1 -acid glycoprotein (glycans 1−3) contains various forms of di-, tri-, and Figure 1 . Histogram of the binding of RNase A to a printed array of mammalian cell-surface glycans. The array had 264 synthetic and natural aminefunctionalized glycoconjugates immobilized on N-hydroxysuccinimide-activated glass slides. 62 In the synthesis of the glycan array, R = (CH 2 ) 5 NH 2 for Globo H and R = (CH 2 ) 2 NH 2 for SSEA-4. Binding was detected by fluorescence using α-RNase A and a fluorescently labeled secondary antibody. Glycans are listed in Table S1 . Several tetrasaccharides and hexasaccharides were also recognized by RNase A. Most prominent in the profile are the hexasaccharides Fucα1−2Galβ1−3GalNAcβ1−3Galα1− 4Galβ1−4Glc (glycan 56) and Neu5Acaα2−3Galβ1−3Gal-NAcβ1−3Galα1−4Galβ1−4Glc (glycan 223), both of which belong to the globo series of glycosphingolipids. 37, 38 Glycan 56 is Globo H. Glycan 223 is the stage-specific embryonic antigen-4, SSEA-4, which is expressed briefly during early stages of development and in certain teratocarcinoma cells. 39, 40 Surprisingly, RNase A appeared to have little affinity for the pentasaccharide precursor to these molecules, Galβ1−3Gal-NAcβ1−3Galα1−4Galβ1−4Glc (glycan 127), but did bind to a similar structure, GalNAcβ1−3Galα1−4Galβ1−4GlcNAc (glycan 90). Together, these results suggest that RNase A recognizes the core tetrasaccharide GalNAcβ1−3Galα1− 4Galβ1−4Glc that constitutes all globo-series glycosphingolipids. 37, 38 Binding of RNases to Immobilized Globo H. To characterize the affinity of RNases for Globo H (glycan 56), we used an assay that displays the glycan on a surface. Specifically, glycan−biotin conjugates were immobilized on avidin plates and incubated with various concentrations of fluorophore-labeled RNases. We found that the RNase 1·Globo H complex has K d = (0.8 ± 0.2) μM ( Figure 2A ; Table 2 ). The affinity of RNase A for Globo H was detectable but significantly weaker, consistent with the lower abundance of this particular glycan in cows (vide infra). We likewise assessed the affinity of RNase A and RNase 1 for immobilized SSEA-4 (glycan 223). Table 2 .
This glycan shares a pentasaccharide unit with Globo H but appeared to have less affinity for RNase A in the glycan array ( Figure 1 ). We found that RNases did indeed bind more weakly to SSEA-4 than to Globo H ( Figure 2C ; Table 2) .
Effect of Globo H on RNase-mediated Cytotoxicity. Globo H has been detected inconsistently in mammals. For example, this glycan is more abundant in tissues from rat than in those from cats and dogs. 41 Analyses of the globo-series glycolipids have not, however, been performed in bovine tissues. Because RNase A is derived from a cow, we probed cells from bovine mammary gland epithelial line MAC-T 42 for three globo-series glycans: Globo H, SSEA-4, and SSEA-3. Using monoclonal antibodies that are specific for these glycans, 27 a fluorescently labeled secondary antibody, and confocal microscopy, we were unable to detect any of these glycans on the surface of MAC-T cells (data not shown). Accordingly, we performed subsequent analyses with human cells.
Variants of RNase A and RNase 1 that evade cytosolic RI are selectively toxic to human cancer cells. For example, variants of RNase 1 (R39D/N67R/N88R/G89R/R91D, or "DRRRD") and RNase A (G88R) demonstrate cytotoxicity against human leukemia cells with IC 50 values of 10.8 and 6.2 μM, respectively.
6,15 Hence, we sought to determine the effect of reducing cell-surface Globo H on RNase-mediated cytotoxicity.
Small-molecule inhibitors of glycosyltransferases can be used to modulate the display of glycans on the cell surface. 43, 44 For example, 2-fluoro-2-deoxyfucose (2FF) inhibits fucosyltransferases. 43 Of the 20 highest scoring ligands in our screen (Table  S2) , only Globo H has a fucose unit. Intracellular esterases Table 2 . Affinity of RNase A and RNase 1 for Surface-Bound Globo H and SSEA-4
a Values (±SE) were obtained by fitting the data in Figure 2 to eq 2. convert peracetylated 2-fluoro-2-deoxyfucose (Ac 3 2FF) into 2FF. 43 We synthesized Ac 3 2FF and used confocal microscopy
and flow cytometry to demonstrate that treating MCF-7 cells with Ac 3 2FF reduces the surface-display of Globo H ( Figure 3A and 3B). Using an assay that measures viable cells, we found that cells with lower Globo H levels were less vulnerable to cytotoxic RNase variants ( Figure 3C ). Finally, we used a highly sensitive assay of cellular DNA synthesis to demonstrate that α- GH antagonizes the cytotoxicity of DRRRD RNase 1 ( Figure  3D ). Globo H Binding Site on RNase 1. To identify the residues in RNase 1 that interact with Globo H, we employed 1 H, 15 N-HSQC NMR spectroscopy. The backbone chemical shifts of RNase 1 exhibited few changes in the presence of zwitterionic CTAB micelles. In contrast, these shifts were perturbed markedly by micelles containing a Globo H−lipid conjugate at 1 equiv relative to RNase 1 ( Figures S3A and  S3B ). These changes in the vector of the chemical shift were calculated with eq 3 and plotted by residue number (Figure 4) . At pH 6.5, major shift perturbations were found throughout the amino acid sequence, being greatest at residues Ser23, Phe46, Val47, Val52, Asn76, Ser77, Tyr92, and Phe120 ( Figure  4A ). These perturbations were mapped onto the structure of RNase 1 to depict those regions that contribute most to the binding of Globo H ( Figure 4B ). The perturbations at pH 6.5 were dispersed along the protein, residing mainly in turns and bends (Table 3) .
RNase 1 undergoes endocytosis, and glycosylaminogylcans reside on the lumen of endosomes. 45 Accordingly, we also used 1 H, 15 N-HSQC NMR spectroscopy to monitor chemical shift perturbations at pH 4.7, which is encountered in endosomes. 46 ,47 Interestingly, we found that the larger overall shift perturbations clustered predominantly to a more polar serinerich loop, Ser18−Thr24, as well as at His80 (Figures 4C and 4D; Table 4 ). As these residues are predominantly polar, the interactions are likely due to hydrogen bonding. These data suggest that the site on RNase 1 that interacts with Globo H is smaller at low pH, and that some of the multivalency that confers tighter binding is lost. These structural data are consistent with the weak affinity of RNase 1 for Globo H at low pH ( Figure 2B ).
We also used 1 H, 15 N-HSQC NMR spectroscopy to identify the residues in RNase A that interact with Globo H at pH 4.7.
We found that few residues were altered ( Figures S3C and S4) , consistent with the weak affinity observed with binding assays ( Figure 2B ).
■ DISCUSSION
We have discovered that a protein and a carbohydrate conspire to direct the degradation of RNA within cancer cells.
Specifically, we found that the major secretory ribonuclease in humans, RNase 1, interacts with a human cell-surface glycan, Globo H, which is a tumor-associated antigen (Figure 1) . The affinity of RNase 1 for this neutral glycan is in the high nanomolar range at physiological pH ( Figure 2A ; Table 2 ). As both RNase 1 and Globo H are the basis for ongoing clinical trials, 10,33 our discovery links two molecules that are now in the clinic. Moreover, our discovery rationalizes the selective cytotoxicity of RNase 1 variants for cancerous versus noncancerous cells while revealing an endogenous ligand for Globo H.
RNases are known to interact with anionic cell-surface glycans. Indeed, sialic acid and heparan sulfate play a role in the cellular uptake of RNases. 2, 16 These
Globo H is a specific ligand for RNase 1. An RNase−Globo H interaction was apparent regardless of whether the glycan was displayed on a slide (Figure 1 ), in the well of a plate (Figure 2 ), or on a micelle ( Figure 4 ). As these three display modes have only Globo H itself in common, their readout validates Globo H as a ligand for RNase 1. Moreover, reducing the display of Globo H on the surface of breast adenocarcinoma cells by two distinct methods (i.e., a small-molecule inhibitor of biosynthesis or a monoclonal antibody antagonist) makes cells less susceptible to a cytotoxic variant of RNase 1 (Figure 3) . We note that cell-surface components change during tumorigenesis, 12 and such changes could amplify selective toxicity that is based on the differential display of Globo H.
RNase A and RNase 1 have 82% identity in their amino acid sequence. Correspondingly, the two enzymes appear to interact with Globo H in a similar manner, albeit with different affinity (Table 2) . Of the eight residues of RNase 1 that were perturbed most upon binding to Globo H at neutral pH, six are conserved in RNase A. Only Val52 and Asn76, which are alanine and tyrosine residues in RNase A, differ. Eight of 11 residues of RNase 1 that were perturbed most upon binding at low pH are in RNase A, with Thr24, His80, and Lys102 of RNase 1 being replaced with serine, asparagine, and alanine, respectively, in RNase A.
Like Globo H, glycosaminoglycans reside on the surface of human cells. Sulfated glycosaminoglycans are known to bind to RNase 1, presumably via favorable Coulombic interactions with the cationic active site. 2, 14, 16, 49 The residues that interact with Globo H are distal from the enzymic active site (Figures 4B and  4D ). Accordingly, RNase 1 could employ multivalency in its binding to human cells. This mode of binding is consistent with an experimental/computational study that concluded that specific (though unidentified) cell-surface components and nonspecific Coulombic interactions both contribute to the cellular uptake of RNase 1.
14 Along with other cell-surface glycans, 45 Globo H is likely displayed on the interior of endosomes following endocytosis. Interestingly, NMR analyses reveal that the binding sites on RNase 1 for Globo H differ with pH (Figure 4) . At acidic pH, these sites cluster and become weaker. These data, which are consistent with observed values of K d (Figures 2A and 2B ; Table 2 ), suggest a mechanism in which RNase 1 is released from lumenal Globo H as endosomes mature, allowing for the entry of RNase 1 into the cytosol. Interestingly, other RNase ligands in the glycan array include sialic acid glycoproteins ( Figure 1 and Table 1 ). These proteins include the transporter, α 1 -glycoprotein, whose role is largely unknown aside from being a carrier that can improve the pharmacokinetics of small-molecule drugs. 50 Ceruloplasmin is a copper-binding protein that associates with transferrin, an ironbinding protein. An interaction with these proteins could enable an unmodified enzyme to avoid renal filtration in vivo. This mechanism could be more advantageous than PEGylation, which increases the circulation time of RNases in mice but at the expense of cellular uptake and enzymatic activity. 51, 52 For over 50 years, thoughts about pancreatic-type ribonucleases have been dominated by RNase A. This renowned enzyme has been the basis for much seminal work in biological chemistry, resulting in the first enzymatic reaction mechanism 53,54 along with four Nobel prizes. 55−57 New work has, however, revealed substantial differences in the biochemical and biological properties of RNase A and its human homologue, RNase 1. 2 We have discovered another difference, and propose that affinity of RNase 1 for Globo H evolved for a specific purpose: to defend the host organism against cancer.
■ METHODS
Materials. MCF-7 cells were from ATCC (Manassas, VA). Phosphate-buffered saline (PBS) (Ca 2+ -and Mg 2+ -free), Dulbecco's modified Eagle's medium (DMEM), and fetal bovine serum (FBS) were from Life Technologies (Grand Island, NY).
A rabbit polyclonal IgG antibody to RNase A (α-RNase A) was from Biodesign International (Kennebunk, ME); a secondary goat α-rabbit IgG−Alexa Fluor 594 conjugate was from Invitrogen (Carlsbad, CA). A murine monoclonal IgM antibody to Globo H (MBr1 or α-GH) was from Enzo (Farmingdale, NY); secondary goat α-mouse IgG−Alexa Fluor 594 and IgG−Alexa Fluor 647 conjugates were from Life Technologies.
[
15 N]-NH 4 Cl was from Cambridge Isotope Laboratories (Andover, MA). 2-Fluoro-2-deoxyfucose was from CarboSynth (San Diego, CA). Dithiothreitol (DTT) was from Goldbio (St. Louis, MO). Cetyltrimethylammonium bromide, 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB), isopropyl β-D-1-thiogalactopyranoside (IPTG), 2-(N-morpholino)ethanesulfonic acid (MES), tris(hydroxymethyl)aminomethane (Tris), Tween X-100, bovine serum albumin (BSA), and other reagents, solvents, and buffers were from Sigma-Aldrich (St. Louis, MO) unless noted otherwise.
Glycan Synthesis. Globo H−biotin and Globo H− ceramide conjugates were synthesized from Globo H as described previously.
24,27,58 SSEA-4−biotin conjugate (Compound No. B295, Lot S284-1) was obtained from the Consortium for Functional Glycomics.
Peracetylated 2-Fluoro-2-deoxyfucose (Ac 3 2FF). Peracetylated 2-fluoro-2-deoxyfucose was prepared from 2-fluoro-2-deoxyfucose by a procedure similar to that described previously. 43 Briefly, 2-fluoro-2-deoxyfucose (10.0 mg, 0.060 mmol) was dissolved in pyridine (0.35 mL), and the resulting solution was cooled to 0°C. Acetic anhydride (0.020 mL, 0.22 mmol) was added, and the reaction vial was covered in foil and allowed to warm to room temperature overnight. The reaction mixture was then diluted with dichloromethane (5 mL) and washed with 1 M HCl (3 × 2 mL), saturated aqueous NaHCO 3 (3 mL), and brine (3 mL). The organics were dried over Na 2 SO 4 (s), concentrated under reduced pressure, and dried by high vacuum to provide peracetylated 2-fluoro-2-deoxyfucose in quantitative yield (17.5 mg; 0.060 mmol). NMR spectra were acquired on a Bruker spectrometer operating at 400 ( + 310.1297; found, 310.1299. Production of RNases. RNase A and RNase 1 were produced by heterologous expression of their cDNA in Escherchia coli strain BL21(DE3) and purification as described previously. 4 For conjugation of BODIPY, a cysteine residue was installed at residue 19 of the RNases with site-directed mutagenesis, and P19C RNase 1 and A19C RNase A were produced in a manner similar to that of the wild-type enzymes. After purification, the nascent thiol was protected as a mixed disulfide by reaction with DTNB. Prior to conjugation, the nascent thiol in 10 mg of protein was deprotected by the addition of DTT (4 equiv). The RNase was separated from excess DTT by passage through a column of PD-10 desalting resin from GE Healthcare (Pittsburgh, PA). The deprotected RNase was reacted with 10 equiv of BODIPY-Fl from Life Technologies dissolved in aqueous DMSO (10% v/v). The BODIPY-Fl solution was added dropwise with stirring, and the reaction was allowed to proceed at room temperature for 2 h, then at 4°C for 4 h. After overnight dialysis into 50 mM AcOH, pH 5.0, purification by chromatography on a cationexchange resin (GE Healthcare) yielded RNase−BODIPY conjugates. The identity of these conjugates was confirmed with matrix-assisted laser desorption/ionization (MALDI) mass spectroscopy at the University of Wisconsin Biotechnology Center and SDS−PAGE imaged by scanning for fluorescence and staining with Coomassie. Ribonucleolytic Activity Assays. RNases were assayed for catalytic activity by monitoring cleavage of a fluorogenic RNA substrate, 6-FAM−dArUdGdA−6-TAMRA from IDT (Coralville, IA). 60 Assays were performed in 0.10 M MES−NaOH [oligo(vinylsulfonic acid)-free 61 ] buffer, pH 6.0, containing NaCl (0.10 M). The addition of RNases yielded a linear increase of fluorescence that can be converted into activity with the equation
where ΔI/Δt is the initial reaction velocity, I max is the maximum detected fluorescence after saturating substrate with excess RNase A, and I 0 is the initial background fluorescence after incubation of substrate. The values of k cat /K M calculated with eq 1 were (31 ± 6) μM −1 s −1 and (2.1 ± 1.2) μM −1 s −1 for RNase A and RNase 1, respectively, and neither fluorescence labeling nor isotopic incorporation had a significant effect on these values.
Glycan Array Screening. A printed array of mammalian glycans was screened for RNase A ligands by the standard procedure of Core H of the Consortium for Functional Glycomics (CFG). 62 The array was version 2.0 and comprised 264 synthetic and natural glycans that are found on the surface of mammalian cells. The gycans were functionalized with an amino group and immobilized to N-hydroxysuccinimideactivated glass slides. Solid-Phase Glycan Binding Assay. Quantification of binding between RNases and immobilized glycans was monitored using a fluorescence surface-binding assay. Briefly, a 96-well plate coated in NeutrAvidin from Pierce (Rockford, IL) was washed with 3× PBS and then treated with 10 equiv of Globo H−biotin or SSEA-4−biotin. To reduce nonspecific interactions, wells were incubated with aqueous milk (5% v/v) and washed with PBS (3×). RNase−BODIPY conjugates were incubated to equilibrium in PBS, pH 7.4, containing Tween X-100 (0.005% v/v) or 20 mM Tris−HCl buffer, pH 5.0, containing NaCl (130 mM). After 3 washes, the fluorescence of an RNase−BODIPY conjugate was detected by emission at 530 nm after excitation at 490 nm. The fluorescence was corrected for that from a well treated with unconjugated biotin, and data were analyzed by nonlinear regression to the equation
where B is the normalized relative fluorescence (RFU), B max is the maximum percent fluorescence, and h is a Hill coefficient. Cell Culture. Cells from the MCF-7 human breast adenocarcinoma line were grown in DMEM (high glucose) containing FBS (10% v/v) and pen/strep from Invitrogen. Cells were maintained at 37°C in 5% CO 2 .
Confocal Microscopy. Globo H on live cells was visualized with confocal microscopy. MCF-7 cells (1 × 10 5 /well) in medium were grown for 3 days in the presence of Ac 3 2FF (100 μM in 0.1% v/v DMSO) 43, 44 or DMSO (0.1% v/v) alone. The medium was replaced with serum-free medium, and cells were plated in an 8-well microscopy slide from Ibidi (Verona, WI 
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